Biotech Daily
Wednesday November 8, 2017

Daily news on ASX-listed biotechnology companies

* ASX FLAT, BIOTECH DOWN: VIRALYTICS UP 10%; PSIVIDA DOWN 9%
* JOHNS HOPKINS COMPLETES SIENNA BLADDER CANCER TEST STUDY
* CLARITY STARTS SARTATE KIDS NEUROBLASTOMA IMAGING TRIAL
* LUINA WINS QUEENSLAND HEALTH, BIOTECHNOLOGY EXPORT AWARD
* FOUR STUDIES BACK IMPEDIMED L-DEX FOR LYMPHOEDEMA
* CRYOSITE: MORE ACCC QUESTIONS ON ASSET SALE TO CELL CARE
* ORTHOCELL REQUESTS CELGRO CE MARK TRADING HALT
* G MEDICAL TAKES INDIA, TAIWAN DISTRIBUTION HALT TO SUSPENSION

MARKET REPORT
The Australian stock market edged up 0.03 percent on Wednesday November 8, 2017 with the ASX200 up 2.0 points to 6,016.3 points.

Just six of the Biotech Daily Top 40 stocks were up, 25 fell, seven traded unchanged and two were untraded. All three Big Caps fell.

Viralytics was the best of the few, up 7.5 cents or 10.1 percent to 81.5 cents with 13,179 shares traded.

Genetic Signatures climbed 9.7 percent; Avita was up 3.8 percent; Starpharma rose 2.1 percent; with both Airxpanders and Polynovo up 1.45 percent.

Psivida led the general retreat, down 14 cents or 8.7 percent to $1.465 with 725 shares traded.

Acrux and Prana lost more than five percent; Admedus, Compumedics and Neuren fell more than four percent; Cyclopharm, Oncosil and Reva were down more than three percent; Bionomics, Dimerix, Ellex, Nanosonics and Uscom shed more than two percent; Clinuvel, Impedimed, ITL, LBT, Mesoblast, Osprey, Pharmaxis, Resmed and Volpara were down more than one percent; with Cochlear, CSL, Opthea, Pro Medicus and Sirtex down by less than one percent.
SIENNA CANCER DIAGNOSTICS
Sienna says that Johns Hopkins Hospital has completed a 500-patient study testing of its telomerase-based in-vitro diagnostic for bladder cancer.
Sienna said that the Baltimore, Maryland-based Johns Hopkins Hospital study investigated the presence of human telomerase reverse transcriptase (hTERT) a cancer-related biomarker in urothelial cells.
The company said that the prospective study began in July 2016 and investigated 500 patients undergoing investigation for bladder cancer by urine cytology and/or cystoscopy, with a six month follow-up to confirm the test results.
Sienna said the results of the study would be presented at the US and Canadian Academy of Pathology meeting in Vancouver, Canada from March 17 to 23, 2018.
Sienna chief executive officer Matthew Hoskin said that having the results of a study on Sienna's adjunct diagnostic for bladder cancer "presented at such a well-attended meeting gives it terrific exposure to a large number of physicians who will have the opportunity to familiarize themselves with the test".
"Johns Hopkins is a renowned research institution that employs researchers who are at the leading edge of their field," Mr Hoskin said. "The fact that the results of the study will be presented by such a prestigious institution adds credibility to the findings."
Sienna fell half a cent or 3.85 percent to 12.5 cents.

CLARITY PHARMACEUTICALS
Clarity says that recruitment has begun at Sydney’s Westmead Children’s Hospital in its 10-patient Sartate Kids trial.
Clarity said its Sartate Kids trial was a multi-centre, open-label, non-randomized, phase I/IIa positron emission tomography imaging trial of paediatric patients with high-risk neuroblastoma using copper-64 sartate.
The company previously said that Sartate was copper-64 labelled octreotate, or 64Cu-Sartate, a positron emission tomography diagnostic used for the localization of somatostatin receptor-positive cancers such as neuroblastomas (BD: Aug 15, 2017).
Clarity said that additional sites in Australia and the US would be activated over the coming months and data from this trial would enable it to progress copper-67 Sartate trials for the therapeutic treatment of neuroblastoma in children.
The company said that neuroblastoma occurred most often in infants and young children younger than five years old and it was the most common type of cancer to be diagnosed in the first year of life, accounting for about 13 percent of paediatric cancer mortality.
Clarity executive chairman Dr Alan Taylor said the company was “well-positioned with its technology to pave the way for better therapies for children with cancer by trying to improve survival rates and significantly reduce long-term side effects”.
Clarity is a public unlisted company.

LUINA BIO
Luina Bio says it has won the Queensland export award for health and biotechnology.
Luina said the state finalists would compete for the National Australian Export Awards on December 5, 2017 in Canberra.
Luina was formerly known as Pharmasynth, which was spun-out from Progen, now TBG Diagnostics, in 2016 and manufactures recombinant proteins, vaccines and synthetic molecules for human and veterinary uses (BD: May 4, 2016).
Luina is a private company.
**Impedimed**

Impedimed says that four study abstracts on its L-Dex lymphoedema diagnostic will be presented at the San Antonio, Texas Breast Cancer Symposium in December, 2017. Impedimed said that the independent studies supported the value of prospective surveillance using L-Dex for the early detection of sub-clinical lymphoedema and the subsequent reduction in chronic breast cancer-related lymphoedema rates. The company said the four abstracts were entitled ‘L-Dex surveillance of breast cancer-related lymphoedema: A retrospective study’, ‘Low rates of chronic breast cancer related lymphedema in a cohort of high-risk patients undergoing prospective surveillance with bio-impedance spectroscopy’, ‘Utilization of BIS in the prevention of chronic breast cancer related lymphedema’ and ‘The impact of a structured surveillance protocol using bio-impedance spectroscopy on preventing breast cancer related lymphedema in high-risk patients’. Impedimed chief executive officer Richard Carreon said that the studies “add to the growing body of clinical evidence on how physicians are able to manage their cancer patients and limit their progression of [breast cancer-related lymphoedema] using L-Dex”. Impedimed fell one cent or 1.3 percent to 77 cents.

**Cryosite**

Cryosite says the Australian Competition and Consumer Commission (ACCC) has “suspended the timeline for the review of the Cell Care Pty Ltd … transaction”. In August, Cryosite said the ACCC would review its proposed licence and sale of assets to Cell Care Australia Pty Ltd (BD: Jun 23, Aug 4, 2017). Cryosite said at that time it proposed to licence the collection, processing and storage of umbilical cord and tissue and to sell certain assets of its cord blood and tissue banking business to Cell Care and focus on its clinical trials logistics and biorepository services. In 2015, Cell Care Australia and related parties reduced their substantial shareholding in Cryosite from 22.96 percent to 19.79 percent (BD: Nov 26, 2015). Today, the company said the ACCC sought additional information and the November 16, date was “vacated”, with a new date to be published when the information was received. Cryosite was untraded at 15 cents.

**Orthocell**

Orthocell has requested a trading halt pending an announcement “in relation to its application for European regulatory approval … of its Celgro collagen medical device”. Trading will resume on November 10, 2017 or on an earlier announcement. Orthocell last traded at 31 cents.

**G (GEVA) Medical Innovations**

G Medical has requested a voluntary suspension to follow the trading halt requested on November 6, pending an announcement relating to distribution of its devices in India and Taiwan (BD: Nov 6, 2017). G Medical last traded at 39 cents.